A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 21 Jan 2019

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs TKM PLK1 (Primary)
Indications Adrenocortical carcinoma; Hodgkin's disease; Neuroendocrine tumours; Non-Hodgkin's lymphoma; Solid tumours
Focus Adverse reactions
Sponsors Tekmira Pharmaceuticals Corporation

07 Jun 2016 Results (n=16) assessing safety and efficacy, presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
27 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
14 May 2015 Planned End Date changed from 1 Jun 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com